Purchase this article with an account.
Karim Diab, Swati Chavda, Nathan Gorfinkel, William Hodge, Brad Dishan, Hargurinder Singh; Visual Outcomes and Adverse Events in Diabetic Macular Edema Treated with VEGF Inhibitors-A Systematic Review. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1759.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
VEGF Inhibitors are being used as part of the standard of care for diabetic macular edema. We did a systematic review to assess the overall efficacy and side effects of these agents for this condition.
Relevant literature was obtained using an exhaustive search from the Medline, Biosis, CINAHL, Cochrane and Web of Science databases. Grey literature that consisted of lectures, seminars and conferences was also retrieved. The results were then inserted into EPPI, the systematic review program. Duplicates were then removed using EPPI after a bibliographic record was made. Literature was then passed through two levels of screening followed by a data extraction level. Papers had to be included after each level of screening in order for data to be extracted from them. EPPI records whether a publication is included or excluded after each level of screening.
24 studies treating 3992 eyes were retrieved. 83% of studies recorded an improvement in mean macular thickness ranging from an average of 16 to 194 microns. 93% of studies recorded an improvement of central vision. 14 cases of endophthalmitis have been reported (0.35%) and 39 cases of retinal detachment (0.98%). 105 cases of vitreous hemorrhage have been reported (2.6%)
VEGF inhibitor treatment for diabetic macular edema shows consistently positive results with few side but potentially serious effects.
This PDF is available to Subscribers Only